Difference between revisions of "Doxepine-escitalopram"

From Psychiatrienet
Jump to: navigation, search
(Redirected page to Doxepine-citalopram)
Line 1: Line 1:
#redirect [[Doxepine-citalopram]]
+
{{Drugswitch
 +
| from = doxepin
 +
| to = escitalopram
 +
| stop =
 +
* '''Before day 1:''' gradually reduce dosage of doxepin to a maximum of 100 mg/day.
 +
* '''Day 1:''' reduce dosage of doxepin to 50 mg/day.
 +
* '''Day 3:''' reduce dosage of doxepin to 25 mg/day.
 +
* '''Day 8:''' stop administration of doxepin.
 +
| start =
 +
* '''Day 1:''' simultaneously start administration of escitalopram in a normal dosage of 10 mg/day.
 +
| info =
 +
* Occurrence of serotonin syndrome is theoretically possible, so caution is necessary.
 +
* Escitalopram is a weak inhibitor of CYP2D6, which metabolizes doxepin. 
 +
}}

Revision as of 00:23, 5 March 2010

Doxepin
Type antidepressant
Group TCA
links
ATC-code N06AA12
Medscape Doxepin
PubChem 3158
PubMed Doxepin
Drugs.com doxepin
Kompas (Dutch) Doxepin
Wikipedia Doxepin
Escitalopram
Type Antidepressant
Group SSRI
links
Medscape Escitalopram
PubChem 10832572
PubMed Escitalopram
Kompas (Dutch) Escitalopram
Wikipedia Escitalopram

Switch medication from doxepin to escitalopram.

Nietinrijdenbord.png Stop doxepin
  • Before day 1: gradually reduce dosage of doxepin to a maximum of 100 mg/day.
  • Day 1: reduce dosage of doxepin to 50 mg/day.
  • Day 3: reduce dosage of doxepin to 25 mg/day.
  • Day 8: stop administration of doxepin.
Eenrichtingbord.png Start escitalopram
  • Day 1: simultaneously start administration of escitalopram in a normal dosage of 10 mg/day.
Infobord.png More information
  • Occurrence of serotonin syndrome is theoretically possible, so caution is necessary.
  • Escitalopram is a weak inhibitor of CYP2D6, which metabolizes doxepin.
  1. 1.0 1.1 1.2 1.3 1.4 KNMP; Informatorium Medicamentorum 2015; Monografie "doxepine" (Dutch)
  2. NVZA; Toxicology.org; Monografie 63 (dutch)
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.